{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-23-000040","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2023-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.550011+00:00","generated_at":"2026-06-13T17:46:03.062101+00:00","sec_items":["1.01","9.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Supernus settles Oxtellar XR patent litigation with Apotex; generic entry allowed Sep 1, 2024","bullets":["Settlement resolves patent litigation with Apotex over generic Oxtellar XR (oxcarbazepine ER).","Apotex granted license to market generic version in U.S. beginning September 1, 2024.","Supernus retains right to market an authorized generic product itself or through third parties.","All claims and counter-claims in the patent litigation will be dismissed."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-23-000040","json":"https://secwatch.observer/filing/0001356576-23-000040.json","markdown":"https://secwatch.observer/filing/0001356576-23-000040.md","text":"https://secwatch.observer/filing/0001356576-23-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000040/0001356576-23-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000040/supn-20230621.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T17:46:03.062101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2350938efbac25b7b1dc94f706195e36f21b0893","claim":"SUPERNUS PHARMACEUTICALS, INC. entered into Settlement and License Agreements with Apotex Inc. and Apotex Corp. (collectively, \"Apotex\") (effective 2023-06-21).","evidence_excerpt":"On June 21, 2023, Supernus Pharmaceuticals, Inc. (\"Supernus\" or the \"Company\") entered into Settlement and License Agreements (the \"Agreements) with Apotex Inc. and Apotex Corp. (collectively, \"Apotex\"), to settle ongoing patent litigation regarding Apotex's filing of an Abbreviated New Drug Application (\"ANDA\") seeking approval to market a generic version of the Company's Oxtellar XR ® (oxcarbazepine) extended-release tablets.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000040/0001356576-23-000040-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"settlement"},{"label":"Counterparty","value":"Apotex Inc. and Apotex Corp. (collectively, \"Apotex\")"},{"label":"Effective","value":"2023-06-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}